Web Analytics

3 Latest Announced Rounds

  • $10,500,000
    Unknown

    3 Investors

    HVAC and Refrigeration Equipment Manufacturing
    Nov 5th, 2024
  • $4,000,000
    Series A
    Financial Services
    Nov 5th, 2024
  • $1,000,000
    Pre-Seed

    1 Investors

    Data Infrastructure and Analytics
    Nov 5th, 2024
$1,349.98M Raised in 67 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Prolocor

start up
United States - Philadelphia, PA
  • 01/03/2024
  • Unknown
  • $1,700,000

There are 50 million people living with chronic coronary artery disease in the U.S., Europe, and Japan. Of these, over 2 million suffer from acute coronary syndrome every year. In each case, the doctor and patient must decide whether to use more powerful therapy to prevent thrombosis – increasing the risk of bleeding – or less intensive therapy – reducing bleeding risk at the expense of more thrombotic events such as heart attack, stroke, and cardiovascular death.

Prolocor’s precision tool will guide treatment decisions, effectively matching the intensity of therapy with the risk of events. Founded by a team that deeply understands thrombosis and cardiovascular disease, Prolocor is building its strategy around platelet FcγRIIa and embarking on a journey to commercialize an innovative precision diagnostic test that quantifies FcγRIIa on the surface of platelets.


Related People

Pete DiBattisteFounder

Pete DiBattiste United States - Philadelphia, Pennsylvania

Specialties: Cardiovascular Disease
Drug Development